Lead Plaintiff Deadline is February 17, 2026

NEW YORK, Dec. 27, 2025 — Purchasers or acquirers of Charming Medical Ltd. (NASDAQ: MCTA) (“Charming”) are reminded that a federal securities class action lawsuit has been filed for investors who bought shares between October 21, 2025 and November 12, 2025, inclusive (the “Class Period”). The deadline to apply for lead plaintiff appointment is February 17, 2026.

The complaint alleges breaches of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The lawsuit claims that after its Initial Public Offering (“IPO”), Charming Medical’s share price saw a swift and artificial climb, jumping from $4.00 to a peak of $29.36 per share without any supporting fundamental news from the company.

Plaintiffs contend this surge was fueled by a fraudulent stock promotion campaign orchestrated on social media. Investigations and media reports indicate that individuals impersonating financial advisors pushed Charming Medical stock in online forums, chat groups, and on social platforms, using exaggerated and baseless claims to encourage retail investors to buy.

Trading in Charming Medical securities was halted in November 2025, an action that allegedly revealed the artificial price inflation and resulted in financial losses for investors.

The proposed class includes all individuals and entities that bought Charming Medical securities during the class period and suffered damages, excluding the defendants and their related parties.

Lead Plaintiff Deadline: Investors have until FEBRUARY 17, 2026 to reach out to the firm to inquire about serving as a lead plaintiff.

Why Wolf Haldenstein:

This distinguished firm, established in 1888, is committed to seeking justice for investors who incurred financial losses due to alleged misrepresentations. The firm leverages more than 125 years of legal experience in securities litigation and has a demonstrated history of defending investor rights.

All affected investors, or those with relevant information, are urged to contact the firm.

Contact:

• Phone: (800) 575-0735 or (212) 545-4774
• Email:
• Contact Person:

Firm Website:

This press release may be deemed Attorney Advertising in certain jurisdictions under applicable law and ethical standards.

SOURCE Wolf Haldenstein Adler Freeman & Herz LLP